Clinical Trial Update: Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and clinical effectiveness of intravitreal bevacizumab (Lumiere) for wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lumiere (bevacizumab)

Snippet

Sponsor: Laboratorio Elea Phoenix S.A. | Conditions: Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED